Nätynki Marjut, Kangas Jaakko, Miinalainen Ilkka, Sormunen Raija, Pietilä Riikka, Soblet Julie, Boon Laurence M, Vikkula Miikka, Limaye Nisha, Eklund Lauri
Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
Biocenter Oulu, University of Oulu, Oulu, Finland.
Hum Mol Genet. 2015 Nov 15;24(22):6374-89. doi: 10.1093/hmg/ddv349. Epub 2015 Aug 28.
Venous malformations (VMs) are localized defects in vascular morphogenesis frequently caused by mutations in the gene for the endothelial tyrosine kinase receptor TIE2. Here, we report the analysis of a comprehensive collection of 22 TIE2 mutations identified in patients with VM, either as single amino acid substitutions or as double-mutations on the same allele. Using endothelial cell (EC) cultures, mouse models and ultrastructural analysis of tissue biopsies from patients, we demonstrate common as well as mutation-specific cellular and molecular features, on the basis of which mutations cluster into categories that correlate with data from genetic studies. Comparisons of double-mutants with their constituent single-mutant forms identified the pathogenic contributions of individual changes, and their compound effects. We find that defective receptor trafficking and subcellular localization of different TIE2 mutant forms occur via a variety of mechanisms, resulting in attenuated response to ligand. We also demonstrate, for the first time, that TIE2 mutations cause chronic activation of the MAPK pathway resulting in loss of normal EC monolayer due to extracellular matrix (ECM) fibronectin deficiency and leading to upregulation of plasminogen/plasmin proteolytic pathway. Corresponding EC and ECM irregularities are observed in affected tissues from mouse models and patients. Importantly, an imbalance between plasminogen activators versus inhibitors would also account for high d-dimer levels, a major feature of unknown cause that distinguishes VMs from other vascular anomalies.
静脉畸形(VMs)是血管形态发生中的局部缺陷,常由内皮酪氨酸激酶受体TIE2基因的突变引起。在此,我们报告了对22种在VM患者中鉴定出的TIE2突变的综合分析,这些突变表现为单个氨基酸取代或同一等位基因上的双突变。通过内皮细胞(EC)培养、小鼠模型以及对患者组织活检的超微结构分析,我们展示了常见的以及特定突变的细胞和分子特征,基于这些特征,突变可聚类成与遗传学研究数据相关的类别。双突变体与其组成的单突变体形式的比较确定了单个变化的致病作用及其复合效应。我们发现,不同TIE2突变体形式的受体运输缺陷和亚细胞定位通过多种机制发生,导致对配体的反应减弱。我们还首次证明,TIE2突变导致MAPK途径的慢性激活,由于细胞外基质(ECM)纤连蛋白缺乏导致正常EC单层丧失,并导致纤溶酶原/纤溶酶蛋白水解途径上调。在小鼠模型和患者的受影响组织中观察到相应的EC和ECM异常。重要的是,纤溶酶原激活剂与抑制剂之间的失衡也可解释高D-二聚体水平,这是一个原因不明的主要特征,可将VM与其他血管异常区分开来。